[2-(4-bromo-pyridin-2-yloxy)-ethyl]-dimethyl-amine | 1142944-58-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [2-(4-bromo-pyridin-2-yloxy)-ethyl]-dimethyl-amine
• 英文别名: 2-((4-Bromopyridin-2-yl)oxy)-N,N-dimethylethanamine；2-(4-bromopyridin-2-yl)oxy-N,N-dimethylethanamine
• CAS: 1142944-58-8
• 化学式: C₉H₁₃BrN₂O
• 分子量: 245.119
• InChiKey: BALXFCSLYKCGAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  25.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  2-氯-4-氨基吡啶 在 硫酸 、 sodium 、 copper(II) sulfate 、 sodium bromide 、 sodium nitrite 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 23.33h， 生成 [2-(4-bromo-pyridin-2-yloxy)-ethyl]-dimethyl-amine
  参考文献：
  名称：

  [EN] ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS
  [FR] INHIBITEURS DE MÉTALLOPROTÉASES MATRICIELLES À BASE D'ARYLSULFONAMIDES

  摘要：

  本发明提供了一种化合物，其化学式为(I)：所述化合物是MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13的抑制剂，因此可用于治疗由MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13异常活性特征的疾病或疾病。因此，化合物(I)的化合物可用于治疗由MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12、和/或MMP-13介导的疾病或疾病。最后，本发明还提供了一种药物组合物。

  公开号：

  WO2009118292A1

文献信息

• ArylSulfonamide Based Matrix Metalloprotease Inhibitors
  申请人：Ehrhardt Claus

  公开号：US20120258954A1

  公开（公告）日：2012-10-11

  The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种式(I)的化合物：该化合物是MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13的抑制剂，因此可用于治疗由MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13异常活性所特征的疾病或疾病。因此，式(I)的化合物可用于治疗由MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了一种制药组合物。
• Arylsulfonamide-based matrix metalloprotease inhibitors
  申请人：Novartis AG

  公开号：US08222424B2

  公开（公告）日：2012-07-17

  The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种化合物，其化学式为(I)：该化合物是MMP-2、MMP-8、MMP-9、MMP-12和/或MMP-13的抑制剂，因此可用于治疗由MMP-2、MMP-8、MMP-9、MMP-12和/或MMP-13异常活性所表现的疾病或疾病。因此，化合物(I)可用于治疗由MMP-2、MMP-8、MMP-9、MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了一种制药组合物。
• Arylsulfonamide based matrix metalloprotease inhibitors
  申请人：Tommasi Ruben Alberto

  公开号：US08362063B2

  公开（公告）日：2013-01-29

  The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种式为（I）的化合物：所述化合物是MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13的抑制剂，因此可用于治疗由MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13异常活性所特征的疾病或疾病。因此，式（I）的化合物可用于治疗由MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了一种制药组合物。
• ArylSulfonamide-Based Matrix Metalloprotease Inhibitors
  申请人：EHRHARDT Claus

  公开号：US20150045398A1

  公开（公告）日：2015-02-12

  The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种化合物(I)：所述化合物是MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13的抑制剂，因此可用于治疗由MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13异常活性所特征化的疾病或疾患。因此，化合物(I)可用于治疗由MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13介导的疾病或疾患。最后，本发明还提供了一种制药组合物。
• ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS
  申请人：Ehrhardt Claus

  公开号：US20110014186A1

  公开（公告）日：2011-01-20

  The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种化合物(I)的公式：该化合物是MMP-2、MMP-8、MMP-9、MMP-12和/或MMP-13的抑制剂，因此可用于治疗由MMP-2、MMP-8、MMP-9、MMP-12和/或MMP-13异常活动所表征的疾病或疾病。因此，公式(I)的化合物可用于治疗由MMP-2、MMP-8、MMP-9、MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了一种制药组合物。